Skip to main content
Equibles
TMCI logo

TMCI · Treace Medical Concepts, Inc. · Metrics

Track TMCI — free

Use TMCI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TMCI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.03 -0.15 (-3.59%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$264.21M
Shares
65.56M
Volume · Nov 6 596.72K Avg daily vol (3M) 274.2K

TMCI metrics

91 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.03
Market cap
$264.21M

Price action

23 metrics
Price change (1W)
-17.4%
Price change (30D)
+7.5%
Price change (3M)
-4.6%
Price change (6M)
+117.7%
Price change (YTD)
+70.6%
Price change (1Y)
-33.1%
Trailing year
Price change (5Y)
-82.5%
52-week high
$6.25
52-week low
$1.20
Change from 52-week high
-33.1%
Change from 52-week low
+248.3%
Annualized volatility
89.1%
Annualized volatility (3M)
64.7%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.7
RSI (14D)
46.2
Price vs SMA 50
-5.1%
Price vs SMA 200
+27.9%
Avg volume (3M)
275,280
Relative volume
1.2
Average dollar volume
$1.23M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
65.56M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.4×
reciprocal yield 69.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 74.8%
P / book
4.4
reciprocal yield 22.7%
FCF yield
-6.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.1×
reciprocal yield 48.7%
EV / revenue historical average (5Y)
4.5×
reciprocal yield 22.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-06
Last earnings
2026-08-07

Profitability

9 metrics
Gross margin
79.6%
Operating margin
-24.4%
Trailing 12 months
Net margin
-27.4%
Gross profit (TTM)
$161.76M
Operating profit (TTM)
−$49.58M
Net income (TTM)
−$55.79M
Trailing 12 months
Diluted EPS (TTM)
$-0.85
FCF margin
-9.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$3.14
Gross profit per diluted share (TTM)
$2.50
Operating profit per diluted share (TTM)
$-0.76
EBITDA per diluted share (TTM)
$-0.65
Net income per diluted share (TTM)
$-0.86
Operating cash flow per diluted share (TTM)
$-0.14
Free cash flow per diluted share (TTM)
$-0.29
Capital expenditures per diluted share (TTM)
$0.15
R&D per diluted share (TTM)
$0.28
Stock compensation per diluted share (TTM)
$0.45
Book value per share
$2.23

Growth

11 metrics
Revenue growth YoY
-3.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$203.35M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.1%
Year over year · more shares
Revenue CAGR (3Y)
+14.5%
Revenue CAGR (5Y)
+30.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-90.5%
Return on assets
-31.1%
Debt / equity
1.0
Current ratio
2.6
EBITDA (TTM)
−$41.95M
Free cash flow (TTM)
−$18.57M
Quick ratio
1.7
Interest coverage
-8.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$20.25M
Latest balance sheet
Cash & equivalents
$7.76M
Total assets
$179.30M
Total debt
$60.05M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.74M
Capital expenditures (TTM)
$9.83M
R&D (TTM)
$18.03M
SG&A (TTM)
—
Stock compensation (TTM)
$28.98M
R&D / revenue
8.9%
Stock compensation / revenue
14.3%

Ownership (13F)

9 metrics
13F filers
117
13F filer change QoQ
-1
Institutional ownership
48.7%
Conviction holders (share of 13F filers)
0.9%
Crowding (high-turnover and private-fund holders)
23.3%
Private-fund adviser ownership
21.4%
Active holders' share change QoQ
-3.2%
Holder tenure
9.3
Price vs estimated holder cost
-40.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.2%

Short interest

3 metrics
Short interest
2.9%
Latest settlement · 8.3 days to cover
Days to cover
8.3d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
$246,654
Insider-sentiment score
83 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1630627 CUSIP 89455T109 13F (30d) 55 filings 43 filers Visit website Investor relations